Related Experiment Videos
Insights
Transplant center performance varies significantly with cyclosporine (CsA) immunosuppression, especially for cadaveric kidney transplants. Centers with better outcomes show a learning curve, while others lag behind, indicating a need for improved CsA protocols.
Area of Science:
- Nephrology
- Immunosuppression Therapy
- Transplantation Medicine
Background:
- Cyclosporine (CsA) is a key immunosuppressant in organ transplantation.
- Variability in transplant center outcomes suggests differences in CsA utilization and management.
- Understanding center-specific performance is crucial for optimizing graft survival.
Purpose of the Study:
- To evaluate one-year graft survival rates in first cadaveric transplant recipients based on transplant center performance using CsA.
- To identify factors contributing to differences in graft survival among transplant centers.
- To assess the impact of CsA on patient and graft survival across different center performance groups.
Main Methods:
- Centers were categorized based on one-year graft survival rates for first cadaveric transplant recipients treated with CsA.
- Comparison of survival rates between CsA and older immunosuppression regimens (azathioprine and prednisone).
- Analysis of pretransplant risk factors (HLA matching, sensitization, demographics, ischemia time) across center groups.
Main Results:
- Significant differences in patient and graft survival were observed among center groups treated with CsA.
- Centers with the poorest survival showed minimal improvement over azathioprine and prednisone.
- A learning curve for CsA effectiveness was evident in high-performing centers, while intermediate centers showed no significant improvement.
- Living-related transplant survival rates were similar across all centers, indicating proficiency with lower-risk procedures.
- Pretransplant recipient and donor risk factors did not explain the observed center effect on CsA outcomes.
Conclusions:
- Transplant center performance significantly impacts outcomes with CsA immunosuppression, particularly for cadaveric transplants.
- The effectiveness of CsA is influenced by a center's experience and potentially its protocols.
- Further investigation into center-specific strategies is warranted to improve CsA efficacy and graft survival, especially in centers with lower performance.
Abstract:
1. Transplant centers were grouped according to one-year graft survival rates of first cadaver transplant recipients treated with CsA. Not surprisingly, the major differences among center groups were associated with the success achieved with CsA in both patient and graft survival. Centers with the poorest survival rates were those with the least improvement over azathioprine and prednisone immunosuppression. 2. There was a definite "learning curve" associated with improvements using CsA immunosuppression for excellent and good centers. Fair centers have yet to see a significant improvement in graft survival overall with CsA. 3. Survival rates for living-related transplants varied little among the center groups, suggesting that most centers do equally well with low-risk transplants. 4. Pretransplant risk factors such as HLA matching, sensitization status, age, sex, and race of the recipients, and ischemia times varied little among the center groups. The center effect cannot be explained by recipient demographic risk factors.